AMGN - アムジェン (Amgen Inc.) アムジェン



symbol AMGN
会社名 Amgen In (アムジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アムジェン(Amgen Inc.)はバイオテクノロジー会社である。同社は多様なヒト治療法を発見・開発・製造・提供する。同社はヒト治療事業を運営する。同社の製品ポートフォリオはNeulasta(ペグフィルグラスチム)、Aranesp(ダルベポエチンアルファ)・EPOGEN(エポエチンアルファ)等の赤血球産生促進剤(ESAs)、Sensipar/Mimpara(シナカルセット)、XGEVA(デノスマブ)、Prolia(デノスマブ)及びNEUPOGEN(フィルグラスチム)、並びにKYPROLIS(カルミゾミブ)、Vectibix(パニツムマブ)、Nplate(ロムリプスチム)、Repatha(エボロクマブ)、BLINCYTO(ブリナトモマブ)、IMLYGIC(タルミモジュラーラパーパープ)、Corlanor(イバブラジン)など他の市販製品を含む。同社は腫瘍/血液学、心臓血管疾患および神経科学の分野における重篤な疾患の治療のためのヒト治療法を提供し、反復性片頭痛治療用Erenumab、骨髄異形成症候群治療用Aranesp、急性リンパ芽球性白血病治療用BLINCYTOおよび転移性メラノーマ治療用IMLYGICを含むフェーズⅢの製品候補を提供する。   アムジェンはバイオ医薬品メ―カ―で、高度な細胞生物学と分子生物学に基づく治療薬の開発、製造、販売を展開する。特にがん、腎臓病、炎症、腫瘍学の分野での治療薬の開発に注力、製品は診療所、透析センタ―、病院に販売される。主要製品は、がん化学療法中の患者や透析患者向けの貧血症治療剤「アラネスプ」、白血球減少症治療剤「ニュ―ラスタ」など。  Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
本社所在地 One Amgen Center Drive Thousand Oaks CA 91320-1799 USA
代表者氏名 Robert A. Bradway ロバート・A・ブラッドウェイ
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 805-447-1000
設立年月日 29312
市場名 NASDAQ National Market System
ipoyear 1983年
従業員数 20800人
EBITDA EBITDA(百万ドル) 12110
終値(lastsale) 205.72
時価総額(marketcap) 133156809623.24
時価総額 時価総額(百万ドル) 133338
売上高 売上高(百万ドル) 23188
企業価値(EV) 企業価値(EV)(百万ドル) 138440
当期純利益 当期純利益(百万ドル) 8464
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Amgen Inc. revenues increased 3% to $11.61B. Net income increased 9% to $4.61B. Revenues reflect Rest of the World segment increase of 9% to $2.51B Other segment increase of 18% to $591M. Net income benefited from Other decrease from $50M (expense) to $22M (income) Foreign currency contracts increase from $14M to $33M (income). Dividend per share increased from $2.30 to $2.64.



   Amgen : How Two Female Staff Members Found a Career in Science | MarketScreener  2020/02/11 05:48:10 MarketScreener
Marissa Strumolo loves science now - even though it wasn't always apparent to her that it could end up being her career. 'I liked to sing,' the 24-year-old Amgen… | February 11, 2020
   Amgen files for mixed shelf  2020/02/10 22:00:05 Seeking Alpha
Amgen (NASDAQ:AMGN) has filed a prospectus for an unspecified mixed shelf offering and the resale of common stock held by certain investors. Shares down 1%
   The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony  2020/02/10 14:03:00 Zacks Investment Research
The Zacks Analyst Blog Highlights: Alphabet, Roche, Amgen, General Electric and Sony
   Amgen Stock Rises 6%  2020/02/05 19:04:00
   Top Analyst Upgrades and Downgrades: Aimmune, Amgen, Biogen, Chevron, CRISPR, Exxon, Nike, Snap, Uber, Ulta, Verizon and More  2020/02/03 14:10:19 24/7 Wall street
   Undervalued Dividend Growth Stocks: May 2019  2019-05-04
Over the past 6 years, I have developed my K.I.S.S. system for investing in dividend growth stocks. The KISS system is a screen that I use each month to identify undervalued dividend growth stocks that I might consider adding to my portfolio. I post my portfolio update each quarter to show all…
   5 Safe And Cheap Dividend Stocks To Invest (April 2019)  2019-04-27
The markets have continued their steady upward trend since the beginning of this year, as visible from the chart below. The market appears to be ready to breach the all-time highs made in Sept. 2018. Therefore, stocks, as represented by the broader indexes, are no longer cheap. S&P 500 …

 関連キーワード  (医薬品 米国株 アムジェン AMGN Amgen Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)